Adicet Bio, Inc.

As of June 30, 2026, Adicet Bio Inc carries a market capitalization of 70.68M, placing it among publicly traded companies globally. Its enterprise value stands at -21.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Adicet Bio Inc's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Adicet Bio Inc has 9.36M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Adicet Bio Inc maintains a current ratio of 6.71, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.70, indicating elevated leverage, while an interest coverage ratio of -1,211.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Adicet Bio Inc posted a negative return on equity (ROE) of -78.08, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -63.62, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 114.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Adicet Bio Inc recorded 125,167.90 in income tax expense. The company reported a pretax loss of -86.51M and -86.63M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Adicet Bio Inc generated - - in revenue and converted that into -86.63M in net income, yielding earnings per share of -9.23. EBITDA reached -85.89M, while operating income came in at -90.78M.

As of June 30, 2026, Adicet Bio Inc holds 103.45M in cash and equivalents against 11.25M in total debt, resulting in a net debt position of -29.00M. Total book value stands at 105.16M, with working capital of 89.95M providing operational flexibility.

Adicet Bio Inc produced -73.99M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -383,381.40 in capital expenditures, free cash flow totaled -74.37M - equivalent to -7.92 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -104.93: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -92.97, meaning Adicet Bio Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Adicet Bio Inc's most recent stock split took place on December 30, 2025 with a 16:1 split ratio.

As of June 30, 2026, Adicet Bio Inc has an Altman Z-Score of -5.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.